FLINT, Mich., Aug. 14, 2017 /PRNewswire/ — EnvoyHealth, a Diplomat company, has agreed to a co-marketing partnership with PharMedQuest for its ARC™ medical benefit drug management platform.
PharMedQuest’s ARC™ program platform will provide EnvoyHealth an advanced solution for managing high-cost oncology drug medications.
ARC™ enables payors and providers to optimize clinical and financial outcomes for treatment of cancer conditions. Through state-of-the art technology and clinical expertise, it offers real-time data that optimally manages oncology therapy under the medical benefit. In partnership, EnvoyHealth and PharMedQuest provide comprehensive oncology management solutions under the pharmacy benefit and medical benefit.
“We are thrilled to expand our service expertise and portfolio by partnering with PharMedQuest,” said Atheer Kaddis, EnvoyHealth’s executive vice president of sales and strategic alignment. “Our full-service model allows us to customize solutions for our partners to demonstrate value, cost-effectiveness, and outcomes to manage the oncology marketplace dynamics. EnvoyHealth’s enhanced service offerings will help our partners meet their objectives in a way that delivers real value.”
“We are excited to partner with EnvoyHealth on this new strategic initiative providing a uniquely innovative approach to managing high-cost oncology drugs,” said Kirby Eng, vice president of business development at PharMedQuest. “Integrating ARC™ with EnvoyHealth’s depth and breadth of complementary specialty drug dispensing, clinical, and patient care management capabilities will enable payors and plan sponsors to collaborate with providers to ensure clinical and cost-effective utilization of high-cost oncology medications for patients afflicted with cancer.”
To learn more about EnvoyHealth, visit envoyhealth.is.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.
EnvoyHealth provides customized services to support pharmaceutical and medical-device manufacturers, payors, hospitals, and health care providers and service organizations. We leverage industry and management expertise to meet the challenges of our clients and the patients they serve. Clients choose us because we are an integral part of their team, tailoring our scalable approach to craft solutions unique to their brand-specific needs and strategic timelines.
EnvoyHealth significantly expanded its offerings through the recent acquisition of WRB Communications Inc. WRB complements EnvoyHealth’s reimbursement hub, noncommercial pharmacy, and clinical research capabilities and adds medical information, remote patient monitoring, inside sales, and customer care capabilities. To learn more about EnvoyHealth, visit envoyhealth.is.
PharMedQuest, an Inc. 5000 company, delivers the highest cost-effective care to patients by investing in optimal resources to build transformational & innovative tools, knowledge, and management for clinicians & payors. Our consulting experience allows us to provide the most robust process, comprehensive insight and sustainable value for our clients. PharMedQuest is ACHC accredited with a distinction in oncology and services include ARC™ medical benefit management, P340B®management, ACE acute & chronic disease patient management and specialty pharmacy services. For more information about PharMedQuest call (714) 364-4008 or visit PharMedQuest.com.
Kali Lucas, Public Relations Specialist
810.768.9580 | email@example.com
Atheer Kaddis, Executive Vice President,
Sales and Strategic Alignment
810.768.9519 | firstname.lastname@example.org
SOURCE EnvoyHealth, a Diplomat company